Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Scilex Holding Company ( (SCLX) ) is now available.
On January 21, 2025, Scilex Holding Company announced an amendment to the maturity date of its Senior Secured Promissory Note with Oramed Pharmaceuticals, extending it from March 21, 2025, to December 31, 2025. This extension involves additional covenants regarding the company’s business conduct and was in consideration of shares delivered by SCLX Stock Acquisition JV. The amendment also includes changes to the ‘Cash Sweep Financing’ definition, allowing Oramed greater discretion in directing repayments.
More about Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company specializing in the acquisition, development, and commercialization of non-opioid pain management products for acute and chronic pain. The company is also exploring treatments for neurodegenerative and cardiometabolic diseases through a proposed joint venture with IPMC Company. Their commercial products include ZTlido, ELYXYB, and Gloperba, and they have several product candidates under development, including SP-102, SP-103, and SP-104.
YTD Price Performance: -3.86%
Average Trading Volume: 2,002,019
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $102.9M
For detailed information about SCLX stock, go to TipRanks’ Stock Analysis page.
